Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962072 | 0.81 | THRB (0.33) | — | |
| SCHEMBL20698993 | 0.81 | MTNR1A (0.36) | MTNR1AMTNR1B | |
| SCHEMBL25067026 | 0.79 | ALDH1A1 (0.38) | MTNR1AMTNR1BAAK1 | |
| SCHEMBL23692311 | 0.79 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL20681241 | 0.79 | MTNR1A (0.37) | MTNR1AMTNR1BHDAC6 | |
| SCHEMBL19475243 | 0.76 | MTNR1A (0.42) | MTNR1AMTNR1B | |
| SCHEMBL20698724 | 0.73 | MTNR1A (0.32) | MTNR1AMTNR1BAAK1 | |
| SCHEMBL19508129 | 0.73 | PSEN1 (0.39) | MTNR1AMTNR1B | |
| SCHEMBL19507082 | 0.73 | GABRA1 (0.46) | MTNR1AMTNR1B | |
| SCHEMBL20681199 | 0.73 | GABRA1 (0.46) | MTNR1AMTNR1BAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MTNR1A 1531/4885MTNR1B 1933/4885AAK1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.